Table 3:
Follow-up serological results of participants for each tested virus and per interface
| Overall | Urban | Semi-urban | Rural | |
|---|---|---|---|---|
| Inclusion, n (%) | 788 (100%) | 304 (38.6%) | 288 (36.5%) | 196 (24.9%) |
| Follow-up, n (%) | 555 (70.4%) | 217 (71.4%) | 203 (70.5%) | 135 (68.9%) |
| Arenavirus | ||||
| IgG seropositive at inclusion | 77 (13.9%) | 52 (24.0%) | 11 (5.4%) | 14 (10.4%) |
| Participants remains seropositive | 28 (36.4%) | 11 (21.2%) | 6 (54.5%) | 11 (78.6%) |
| IgG seroconversion* | 84 (17.6%) | 10 (6.1%) | 21 (10.9%) | 53 (43.8%) |
| Hantavirus | ||||
| IgG seropositive at inclusion | 57 (10.3%) | 29 (13.4%) | 18 (8.9%) | 10 (7.4%) |
| Remain seropositive | 51 (89.5%) | 27 (93.1%) | 17 (94.4%) | 7 (70.0%) |
| IgG seroconversion* | 6 (1.2%) | 2 (1.1%) | 1 (0.5%) | 3 (2.4%) |
| HEV | ||||
| IgG seropositive at inclusion | 130 (23.4%) | 85 (39.2%) | 32 (15.8%) | 13 (9.6%) |
| Remain seropositive | 125 (96.2%) | 82 (96.5%) | 31 (96.9%) | 12 (92.3%) |
| IgG seroconversion* | 9 (2.1%) | 6 (4.5%) | 2 (1.2%) | 1 (0.8%) |
Data are n (%)
*
Participant presenting a seronegative result at inclusion and seropositive result at follow-up visit